Intercept Pharmaceuticals

^{Priced, Nasdaq: ICPT}

Developing novel synthetic therapeutics for chronic liver diseases.

Industry: Health Care

First Day Return: +29.3%

ICPT

Developing novel synthetic therapeutics for chronic liver diseases.

IPO News for Intercept Pharmaceuticals

Biotech IPOs Focused on NASH 03/04/19
Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO 04/02/14
Nine US IPO pricings cap busiest period since early 2011 10/12/12

IPO Data
IPO Date	10/10/2012
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$75
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.interceptpharma.com
Headquarters	New York, NY, United States
Founded	2002
Employees at IPO	18

IPO News for Intercept Pharmaceuticals

Biotech IPOs Focused on NASH 03/04/19
Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO 04/02/14
Nine US IPO pricings cap busiest period since early 2011 10/12/12

Intercept Pharmaceuticals (ICPT) Performance